Atara Biotherapeutics, Inc.
ATRA
$7.94
-$0.08-1.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 475.53% | 1,404.02% | 2,111.34% | 809.03% | -39.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 475.53% | 1,404.02% | 2,111.34% | 809.03% | -39.63% |
| Cost of Revenue | -21.74% | -26.01% | -25.12% | -25.12% | -18.50% |
| Gross Profit | 120.31% | 81.87% | 66.18% | 48.52% | 12.43% |
| SG&A Expenses | -15.18% | -22.63% | -19.82% | -26.13% | -25.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.57% | -25.40% | -24.22% | -25.31% | -19.85% |
| Operating Income | 98.54% | 70.91% | 58.19% | 44.35% | 15.50% |
| Income Before Tax | 93.27% | 69.06% | 54.13% | 40.55% | -8.45% |
| Income Tax Expenses | -311.76% | -180.00% | 200.00% | -54.29% | -50.00% |
| Earnings from Continuing Operations | 93.29% | 69.07% | 54.12% | 40.55% | -8.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.29% | 69.07% | 54.12% | 40.55% | -8.44% |
| EBIT | 98.54% | 70.91% | 58.19% | 44.35% | 15.50% |
| EBITDA | 101.04% | 72.29% | 59.30% | 45.14% | 15.71% |
| EPS Basic | 93.03% | 80.29% | 63.01% | 46.76% | -1.74% |
| Normalized Basic EPS | 94.61% | 81.22% | 65.83% | 49.08% | 19.68% |
| EPS Diluted | 92.97% | 80.28% | 63.00% | 46.76% | -1.66% |
| Normalized Diluted EPS | 94.54% | 81.22% | 65.83% | 49.08% | 19.65% |
| Average Basic Shares Outstanding | 90.58% | 76.71% | 40.68% | 22.67% | 11.93% |
| Average Diluted Shares Outstanding | 91.05% | 76.71% | 40.68% | 22.67% | 11.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |